Form 4: Aclaris Therapeutics Interim CEO Neal Walker Reports Stock Transactions
SEC Form 4 Filing
Interim CEO of Aclaris Therapeutics, Neal Walker, reports acquisition and disposal of common stock and restricted stock units.
Summary
- On November 1, 2024, Neal Walker, Interim President and CEO of Aclaris Therapeutics, engaged in transactions involving the company's common stock and restricted stock units.
- Walker acquired 9,467 shares of common stock through the vesting of restricted stock units.
- Simultaneously, 2,721 shares were disposed of to satisfy tax withholding obligations at a price of $2.09 per share.
- Following these transactions, Walker directly owns 1,376,388 shares of Aclaris Therapeutics common stock and 56,800 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the number of shares held by a key executive, but the overall impact is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 11/01/2024 | Date of stock transactions: acquisition of 9,467 shares via restricted stock units and disposal of 2,721 shares for tax obligations. |
| 02/01/2024 | Start date for monthly vesting of restricted stock units over 15 months. |
| 11/05/2024 | Date of signature by Attorney-in-Fact, Matthew Rothman. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.